Jewell Laboratories is commercializing intellectual property developed at Purdue University in the lab of Dr. David H. Thompson. The company’s first product will be an effective treatment for Niemann-Pick Type C (NPC). Jewell has developed a family of long-circulating cyclodextrin polymers which act as mobilizing agents to induce natural elimination of cholesterol from the body. Animal studies have shown extension of lifespan by 40% and restoration of normal metabolic activity in patient-derived NPC cells by rebalancing cholesterol levels. Additionally, the therapeutic effects can be maintained at a reduced dose and treatment frequency, when compared to competitive alternatives, with a reduction in disease burden in liver, spleen, lung, and other organs that NPC affects.